Nordic Capital posts millions of euros in Leo Pharma – gets owner's share at under 25 percent
The private equity firm Nordic Capital posts EUR 450m in Leo Pharma and gets an owner's share of under 25 percent in the company. The money will go towards supporting the firm's 2030 strategy, while the notion of getting listed is on the table as a possible exit strategy for Nordic Capital in the long term.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
After having been the sole owner of Leo Pharma for 35 years, the Leo Foundation now invites one of the Nordics' largest capital funds, Nordic Capital, into the owner group of Denmark's oldest pharmaceutical company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma struggles with lawsuit in the US
For subscribers
MC2 Therapeutics aims to lead psoriasis market
For subscribers
